论文信息 - 265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC) - 字舞流文

265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

W. Gradishar | Siraj M. Ali | J. O’Shaughnessy | J. Mansi | M. Lehnert | C. Palmieri | G. Clack | L. Kenny | M. Krebs | S. Howell | E. Ainscow | R. Jeselsohn | R. Coombes | S. Sardesai | A. Bahl | S. Lord | P. Richards | H. Arkenau | S. McIntosh | Z. Mitri